CD34 selection as a stem cell purging strategy for neuroblastoma: preclinical and clinical studies.
BACKGROUND
The suitability of CD34 selection for purging peripheral blood progenitor cells (PBPC) collected from patients with neuroblastoma (NB) has been called into question, largely because of reports of detection of low levels of CD34 on the surface of some NB cell lines and tumors.


METHODS
We used three approaches to address the issue of purging of NB from stem cell specimens and possible labeling of NB: 1) Flow cytometric detection of CD34 on NB cell lines. We assessed CD34 expression using a panel of anti-CD34 monoclonal antibodies (MoAbs) including 9C5, 12.8, and QBend10 and showed no increase in labeling over secondary-only control. 2) Spiking experiments with the Isolex 50 system. NB cell lines were used to contaminate aliquots of PBPC collections, after which the products were purified using the Isolex 50. Purging of NB was assessed by quantitative multiplex RT-PCR (TaqMan system) using a tumor-specific transcript, GAGE. We demonstrated >2 logs of tumor cell depletion from these specimens. 3) Analysis of clinical specimens. PBPC pre- and post-CD34 selection were analyzed from patients treated on the CHP-594 transplant trial.


RESULTS
In nine specimens selected using the Ceprate LC CD34 selection system where tumor was detectable by immunocytochemistry preselection, we observed >2.4 to >4.6 logs of NB purging after selection. We then analyzed 23 aliquots of PBPC infused into patients post-CD34 selection and compared them to the product preselection; 20/23 specimens showed depletion of NB, although some level of GAGE message was observed in most post-CD34 selection specimens.


CONCLUSIONS
These data show that purging of NB from PBPC specimens using CD34 selection is feasible, yielding infused products that are negative at the level of ICC but often positive at the level of RT-PCR.
Donovan
J
J
Department of Adult Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
Temel
J
J
Zuckerman
A
A
Gribben
J
J
Fang
J
J
Pierson
G
G
Ross
A
A
Diller
L
L
Grupp
S A
SA
D018952:Antigens, CD34 / Q000032:analysis*; D016465:Bone Marrow Purging; D002648:Child; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D009447:Neuroblastoma / Q000276:immunology*; D013234:Stem Cells; D014407:Tumor Cells, Cultured
D018952:Antigens, CD34